🔎 Trials Near Me

Hjem › Sklerodermi › Illinois › Chicago

Sklerodermi kliniske forsøg i Chicago, IL

10 studier for Sklerodermi søger deltagere på steder i og omkring Chicago (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

RekruttererFase 3
  • Northwestern University, Chicago
  • The University of Chicago Medical Center, Chicago
Alder 18 og opefter · Alle køn · Opdateret 30. sep. 2026 · NCT07497087

A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

RekruttererFase 2
  • University of Illinois Health Outpatient Care Center, Chicago
Alder 18 og opefter · Alle køn · Opdateret 24. sep. 2026 · NCT06655155

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

RekruttererFase 1
  • The University of Chicago Medical Center, Chicago
Alder 18 til 74 · Alle køn · Opdateret 10. sep. 2026 · NCT07085104

A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease

RekruttererFase 2/3
  • GSK Investigational Site, Chicago
Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT05878717

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

RekruttererFase 1
  • Northwestern Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago
Alder 18 til 70 · Alle køn · Opdateret 28. aug. 2026 · NCT06925542

Platform Clinical Study for Conquering Scleroderma

RekruttererFase 2
  • The University of Chicago Medical Center (UCMC), Chicago
Alder 18 og opefter · Alle køn · Opdateret 18. aug. 2026 · NCT06195072

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

RekruttererFase 2/3
  • Northwestern Memorial Hospital, Chicago
  • The University of Chicago Medical Center, Chicago
Alder 18 til 75 · Alle køn · Opdateret 17. aug. 2026 · NCT06328777

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

RekruttererFase 1/2
  • Nkarta Investigational Site, Chicago
Alder 18 til 75 · Alle køn · Opdateret 7. aug. 2026 · NCT06733935

A Study of AZD0120 in Autoimmune Diseases

RekruttererFase 1
  • Research Site, Chicago
Alder 18 til 75 · Alle køn · Opdateret 28. jul. 2026 · NCT07295847

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

RekruttererFase 2
  • aTyr Investigative Site, Chicago
  • aTyr Investigative Site, Chicago
  • aTyr Investigative Site, Chicago
Alder 18 og opefter · Alle køn · Opdateret 7. maj 2025 · NCT05892614

Sklerodermi forsøg i andre byer

Andre studier i Chicago

Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.